Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of SEBI Circular No. SEBI / HO / MIRSD / MIRSD_RTAMB / P / CIR / 2022 / 8 dated January 25, 2022, Aurobindo Pharma has informed that it enclosed the details of ‘Letter(s) of Confirmation’ issued by the Company to its shareholder, in lieu of share certificate(s) reported as lost by him.
The above information is a part of company’s filings submitted to BSE.
